CAMBRIDGE, Mass. — MindImmune Therapeutics, a private biotechnology company developing therapies aimed at the inflammatory drivers of neurodegenerative diseases, announced that it has closed a $10.2 million extension to its Series A financing, bringing the total raised in the round to $30 million. The company also appointed Isaac Stoner as Chief Executive Officer and named both Mr. Stoner and Reetika Bhardwaj of Dolby Family Ventures to its Board of Directors. Founding CEO Stevin Zorn, Ph.D., will transition to the role of Chief Scientific Officer.
Mr. Stoner said he is honored to join the company at a pivotal stage.
“Dr. Zorn and his co-founders have made a fundamental discovery that will change how we think about neurodegenerative diseases. MindImmune’s therapeutic programs have the potential to dramatically benefit Alzheimer’s patients by targeting the underlying inflammatory processes that damage synapses and blood vessels in the brain,” Mr. Stoner said. “I feel fortunate to be leading this talented company as we advance an important first-in-class therapeutic into clinical development.”
Mr. Stoner brings more than 18 years of experience in life sciences entrepreneurship and company formation. He most recently served as entrepreneur-in-residence at Slater Technology Fund and has advised and invested at KdT Ventures. From 2017 to 2025, he co-founded and led Octagon Therapeutics as CEO. His prior roles include positions at Firefly BioWorks, Ion Torrent Systems, PureTech Health, the Martin Trust Center for MIT Entrepreneurship, Action Potential Venture Capital and Genome Corp. He also co-founded the nonprofit Operation Thonapa. Mr. Stoner holds a biomedical engineering degree from Brown University and an MBA from the MIT Sloan School of Management.
The Series A extension was led by Dolby Family Ventures, with participation from Pfizer Ventures, Gates Frontier, Slater Technology Fund, RightHill Ventures, the Foundation for a Better World and others. Funding will support advancement of MindImmune’s lead candidate, MITI-101, into Phase 1 clinical studies. MITI-101 is a monoclonal antibody designed to prevent peripheral immune cells from entering the brain and driving neuroinflammation associated with Alzheimer’s disease progression.
“We’ve been deeply impressed by the progress MindImmune has made since our initial investment, and we believe that Isaac is well positioned to lead MindImmune as the company grows,” said Reetika Bhardwaj, Principal at Dolby Family Ventures. “The company’s novel approach to modulating neuroinflammation has the potential to change the treatment paradigm for Alzheimer’s and other neurodegenerative diseases.”
